AIMS: We evaluated the associations of diabetic complications and underlying pathology with daily walking activity in type 2 diabetic patients without manifest mobility limitations. METHODS: 100 persons with type 2 diabetes (mean age 64.5 ± 9.4 years) were studied. Persons with manifest mobility limitations were excluded. Possible determinants measured: peripheral neuropathy, neuropathic pain, peripheral arterial disease, cardiovascular disease, decreased muscle strength (handgrip strength), BMI, depression, falls and fear of falling. Walking activity was measured during one week with a pedometer. Functional capacity was measured with the 6 min walk test, the timed "up and go" test and a stair climbing test. RESULTS: prevalence of neuropathy (40%) and obesity (53%) was high. Persons took a median of 6429 steps/day. In multivariate regression analysis, adjusted for age and sex, neuropathy was associated with a reduction of 1967 steps/day, decreased muscle strength with 1782 steps/day, and an increase in BMI of 1 kg/m(2) with a decrease of 210 steps/day (all p<0.05). Decreased muscle strength and BMI, but not neuropathy, were associated with outcome of functional capacity tests in multiple regression analysis. CONCLUSIONS: peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. 2010 Elsevier Ireland Ltd. All rights reserved.
AIMS: We evaluated the associations of diabetic complications and underlying pathology with daily walking activity in type 2 diabeticpatients without manifest mobility limitations. METHODS: 100 persons with type 2 diabetes (mean age 64.5 ± 9.4 years) were studied. Persons with manifest mobility limitations were excluded. Possible determinants measured: peripheral neuropathy, neuropathic pain, peripheral arterial disease, cardiovascular disease, decreased muscle strength (handgrip strength), BMI, depression, falls and fear of falling. Walking activity was measured during one week with a pedometer. Functional capacity was measured with the 6 min walk test, the timed "up and go" test and a stair climbing test. RESULTS: prevalence of neuropathy (40%) and obesity (53%) was high. Persons took a median of 6429 steps/day. In multivariate regression analysis, adjusted for age and sex, neuropathy was associated with a reduction of 1967 steps/day, decreased muscle strength with 1782 steps/day, and an increase in BMI of 1 kg/m(2) with a decrease of 210 steps/day (all p<0.05). Decreased muscle strength and BMI, but not neuropathy, were associated with outcome of functional capacity tests in multiple regression analysis. CONCLUSIONS:peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: J Matt McCrary; David Goldstein; David Wyld; Robert Henderson; Craig R Lewis; Susanna B Park Journal: J Cancer Surviv Date: 2019-06-06 Impact factor: 4.442
Authors: Patricia M Kluding; J Robinson Singleton; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; A Gordon Smith; Robin L Marcus Journal: Phys Ther Date: 2017-01-01
Authors: Patricia M Kluding; Mamatha Pasnoor; Rupali Singh; Linda J D'Silva; Min Yoo; Sandra A Billinger; Joseph W LeMaster; Mazen M Dimachkie; Laura Herbelin; Douglas E Wright Journal: Phys Ther Date: 2014-10-02
Authors: Brittney S Lange-Maia; Jane A Cauley; Anne B Newman; Robert M Boudreau; John M Jakicic; Nancy W Glynn; Sasa Zivkovic; Thuy-Tien L Dam; Paolo Caserotti; Peggy M Cawthon; Eric S Orwoll; Elsa S Strotmeyer Journal: J Aging Phys Act Date: 2016-08-24 Impact factor: 1.961
Authors: T Veni; S Boyas; B Beaune; H Bourgeois; A Rahmani; S Landry; A Bochereau; S Durand; B Morel Journal: Support Care Cancer Date: 2018-06-24 Impact factor: 3.603